Industry / United Kingdom
If you would like to subscribe to Americas Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Americas Pharma & Healthcare Insight please click on the trial link below.
GlaxoSmithKline To Take On Merck & Co In Rotavirus Immunisation Market
June 2008 | Industry NewsSorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Americas Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Americas Pharma & Healthcare Insight please click on the trial link below.
GlaxoSmithKline (GSK) and Merck & Co are set to go head-to-head in childhood rotavirus vaccination, after the US Centre for Diseases Control and Prevention (CDC)'s Advisory Committee on Immunization Practices (ACIP) recommended GSK's Rotarix for routine childhood immunisations. Rotarix will now compete directly with Merck's Rotateq which was recommended in